CAP Profiles

Bio

Bio

I care for medically ill children and their families providing support mainly in the hospital setting and at times outpatient care. I also supervise neuro-psycho pharmacology clinic with pediatric neurology where we see neurology and psychiatry patients simultaneously.

My interest is mainly in psychosomatic medicine, however I also specialize in mood disorders and ADHD.

My original graduate degree is in ancient Greek and Latin literature. I have a fondness for the use of narrative in medicine and developmental case formulation. I worked for 8 years prior to medical school and was teacher for 6th-12 graders and college students. I enjoy teaching and writing. I oversee general residents rotating on Child Psychiatry. I am also an assistant editor for the journal, Academic Psychiatry.

Clinical Focus

  • Psychiatry
  • Child Psychiatry
  • Psychosomatic Medicine
  • Mood Disorders
  • Child and Adult ADHD

Academic Appointments

Administrative Appointments

  • Site Director, Child Psychiatry Rotation for General Residents, Child and Adolescent Psychiatry, Stanford (2011 - Present)
  • Committee Member, American Academy of Child and Adolescent Psychiatry, Ethics Committee (2011 - 2013)

Professional Education

  • Fellowship:Stanford University School of Medicine (2010) CA
  • Residency:University of Pennsylvania School of Medicine (2008) PA
  • Medical Education:Drexel University College of Medicine (2004) PA
  • Board Certification: Child and Adolescent Psychiatry, American Board of Psychiatry and Neurology (2012)
  • Board Certification, American Board of Psychiatry and Neurology, Child Psychiatry (2012)
  • Board Certification: Psychiatry, American Board of Psychiatry and Neurology (2011)

Contact

  • Child Adolescent Psychiatry Clinic 401 Quarry Rd MC 5719 Stanford, CA94305
    • Tel: (650) 723-5511
    Fax: (650) 724-7389

Research & Scholarship

Current Research and Scholarly Interests

Ethics in Psychiatry, Mood disorders, Psychosomatic Medicine

Teaching

Graduate and Fellowship Programs

Publications

All Publications

  • Preparing and Training the College Mental Health Workforce. Academic psychiatry Riba, M., Kirsch, D., Martel, A., Goldsmith, M. 2015; 39 (5): 498-502

    View details for DOI 10.1007/s40596-015-0406-x

    View details for PubMedID 26307363

  • Medical Student Education in Psychiatry: An International Affair ACADEMIC PSYCHIATRY Goldsmith, M., Bryden, P. 2014; 38 (3): 361-363

    View details for DOI 10.1007/s40596-014-0120-0

    View details for Web of Science ID 000337143800022

    View details for PubMedID 24789480

  • Ethical Considerations in Child and Adolescent Psychiatry Focus: The Journal of Lifelong Learning in Psychiatry Michelle D. Goldsmith, Shashank V. Joshi 2012; X (2): 315
  • Antidepressants and Psychostimulants in Pediatric Populations Is there an Association with Mania? PEDIATRIC DRUGS Goldsmith, M., Singh, M., Chang, K. 2011; 13 (4): 225-243

    Abstract

    This article reviews the literature that examines whether exposure to psychostimulants or antidepressants precipitates or exacerbates manic symptoms, or decreases the age at onset of mania in pediatric populations. A PubMed search using relevant key words identified studies targeting five distinct clinical groups: (i) youth without a diagnosis of bipolar disorder (BD) at the time of exposure to psychostimulants; (ii) youth with a diagnosis of BD at the time of exposure to psychostimulants; (iii) youth without a diagnosis of BD at the time of exposure to antidepressants; (iv) youth with a diagnosis of BD at the time of exposure to antidepressants; and (v) youth who develop BD after exposure to these medications. In patients with attention-deficit hyperactivity disorder (ADHD), the risk for mania was found to be relatively low with the use of psychostimulants. For patients with BD and ADHD, effective mood stabilization is important prior to adding a stimulant. For children with depression and/or anxiety, the risk of antidepressant-induced mania (AIM) was generally low (<2%), but the risk of general 'activation' secondary to a selective serotonin reuptake inhibitor (SSRI) may be greater (2-10%). However, rates of AIM in specialty clinics appear to be much higher. SSRIs may be particularly problematic in specific populations, such as those with some symptoms of mania or a family history of BD, but the precise risk is unknown. There is no clear evidence that stimulants or SSRIs accelerate the natural course of BD development in overall samples, but in individual cases prescribers should proceed cautiously when using these agents in youth already at risk for developing BD, such as those with ADHD and mood dysregulation, a history of prior AIM, a history of psychosis, or a family history of BD.

    View details for Web of Science ID 000292996000004

    View details for PubMedID 21692547